Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LavipharmATH:LAVI +1.11%82 Net Margin % is 9.37% as of Dec. 2025, which is 69% above its 10-year median of 5.56. GuruFocus rates ATH:LAVI with a GF Score™ of 82/100 and a GF Value™ of €1.19 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 962 Drug Manufacturers companies, Lavipharm ranks better than 62.37% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Lavipharm's Net Income for the
six
months ended in Dec. 2025 was €3.36 Mil. Lavipharm's Revenue for the
six
months ended in Dec. 2025 was €35.88 Mil. Therefore, Lavipharm's net margin for the quarter that ended in Dec. 2025 was 9.37%.
The historical rank and industry rank for Lavipharm's Net Margin % or its related term are showing as below:
ATH:LAVI'
s Net Margin % Range Over the Past 10 Years
Min: 2.14 Med: 5.56 Max: 40.64
Current: 9.57
ATH:LAVI's Net Margin % is ranked better than 62.37% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.37
vs ATH:LAVI: 9.57
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Lavipharm Net Margin % Related Terms
Lavipharm Net Margin % Historical Data
* Premium members only.
The historical data trend for Lavipharm's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATH:LAVI vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lavipharm's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lavipharm Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lavipharm's Net Margin % distribution charts can be found below:
* The bar in red indicates where Lavipharm's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lavipharm (ATH:LAVI) has a Net Margin % of 9.37% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Lavipharm and its competitors. This is 69% above median its historical median of 5.56. Over the past decade, Lavipharm's Net Margin % has ranged from 2.14 to 40.64. According to the industry distribution chart, Lavipharm ranks #362 out of 962 companies in the Drug Manufacturers industry, placing it in the top 37.6%.
Is Lavipharm's Net Margin % too high?
Lavipharm's current Net Margin % of 9.37% is 69% above median its 10-year median of 5.56. Over the past 10 years, this metric has ranged from a low of 2.14 to a high of 40.64. The Drug Manufacturers industry median Net Margin % is 5.37. Lavipharm's value of 9.37% is 74.5% above this industry median. Based on the distribution chart, Lavipharm ranks #362 out of 962 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lavipharm has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lavipharm's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lavipharm ranks #362 out of 962 companies for Net Margin %. This puts Lavipharm in the upper half of its industry. The industry median Net Margin % is 5.37. Lavipharm's value of 9.37% is 74.5% above this benchmark. Historically, Lavipharm's own Net Margin % has ranged from 2.14 to 40.64 over the past decade. While the company's 10-year median is 5.56 vs. the industry median of 5.37, Lavipharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.37, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lavipharm's current Net Margin % of 9.37% is 74.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Lavipharm and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lavipharm's current Net Margin % is 9.37%, which is 69% above median its own 10-year median of 5.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lavipharm stock overvalued right now?
Based on GuruFocus' analysis, Lavipharm (ATH:LAVI) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.19, compared to a current price of €1.64 — trading 37.8% above its estimated fair value. The current Net Margin % is 9.37%, which is 69% above median its 10-year median of 5.56 and 74.5% above the Drug Manufacturers industry median of 5.37. Lavipharm's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Lavipharm (ATH:LAVI), the current Net Margin % is 9.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lavipharm (ATH:LAVI) Overvalued in 2026?
Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued.
The current stock price of €1.64 is trading 37.8% above its estimated GF Value™ of €1.19.
GuruFocus considers Lavipharm to be Significantly Overvalued.
Key valuation signals for ATH:LAVI:
Net Margin %: 9.37% (69% above median its 10-year median of 5.56)
GF Value™: €1.19 vs. price of €1.64 (37.8% above fair value)
Industry Position: 74.5% above the Drug Manufacturers median (#362 of 962)
No single metric tells the full story. See the ATH:LAVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
82GF Score
Get the complete analysis for ATH:LAVI
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATH:LAVI has been successfully added to your 
